The anti-apoptotic BCL2 inhibitor venetoclax (VEN) in combination with HMA or with a low dose of cytarabine has shown unprecedented efficacy in AML, and it is currently approved by the FDA and EMA for the treatment of first-line unfit AML patients [42]. The gene discussed is BCL2; the disease is acute myeloid leukemia.